Direct Renin Inhibitors Industry Global Overview: Market Size, Growth Insights and Forecast
Report ID : 1311462 | Published : May 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Direct Renin Inhibitors Industry is categorized based on Drug Type (Aliskiren, Other Direct Renin Inhibitors) and Application (Hypertension Treatment, Heart Failure Management, Diabetic Nephropathy, Others) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
The Direct Renin Inhibitors Industry, valued at USD 1.2 billion in 2023, is anticipated to expand to USD 2.5 billion by 2033 at a CAGR of 7.6% from 2024 to 2033. This report covers different segments and offers an analysis of the substantial trends and factors affecting the market.
The market for Direct Renin Inhibitors, or DRIs, is relatively new when compared to other constituents of the pharmaceutical market and targets the management of hypertension and other related cardiovascular illnesses. As providers and researchers delve deeper, exploring new therapeutic possibilities, DRIs are being recognized for their capability to directly block renin, an enzyme critical in controlling blood pressure. This mode of action offers not only an alternative to classical antihypertensives but also a powerful means for solving some of the inadequacies of current treatments among stubborn patient groups.
There is clear focus on personalized medicine along with increase in the number of people suffering from hypertension worldwide indicates noteworthy prospects for growth of Direct Renin Inhibitors market. Important market participants are focusing on DRIs to improve the effectiveness of the medication while reducing the side effects associated with the drug. This will allow for more new product introductions and new uses. In addition, more effective management strategies for cardiovascular diseases are in high demand along with better awareness which is favorable for both new and well-established pharmaceutical companies.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | Novartis AG, Roche Holding AG, Merck & Co. Inc., Pfizer Inc., AstraZeneca PLC, Sanofi S.A., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, GSK (GlaxoSmithKline) PLC, Hikma Pharmaceuticals PLC |
| SEGMENTS COVERED |
By Drug Type - Aliskiren, Other Direct Renin Inhibitors
By Application - Hypertension Treatment, Heart Failure Management, Diabetic Nephropathy, Others
By Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Direct Renin Inhibitors Industry Dynamics
The Direct Renin Inhibitors Industry is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Direct Renin Inhibitors Industry Segmentations
Market Breakup by Drug Type
- Overview
- Aliskiren
- Other Direct Renin Inhibitors
Market Breakup by Application
- Overview
- Hypertension Treatment
- Heart Failure Management
- Diabetic Nephropathy
- Others
Market Breakup by Distribution Channel
- Overview
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Direct Renin Inhibitors Industry
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- Novartis AG
- Roche Holding AG
- Merck & Co. Inc.
- Pfizer Inc.
- AstraZeneca PLC
- Sanofi S.A.
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- GSK (GlaxoSmithKline) PLC
- Hikma Pharmaceuticals PLC
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved